| scholarly article | Q13442814 |
| P2093 | author name string | Steven P Braithwaite | |
| Peter H Reinhart | |||
| Weili Duan | |||
| Warren D Hirst | |||
| Steven M Riddle | |||
| Wayne Stochaj | |||
| Pooja Pungaliya | |||
| Eugene L Brown | |||
| Vasanti S Anand | |||
| Kerri Lipinski | |||
| Kerry Kelleher | |||
| Laurie J Reichling | |||
| Richard Somberg | |||
| P2860 | cites work | Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity | Q22254785 |
| GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease | Q24294785 | ||
| The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity | Q24297634 | ||
| Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration | Q24298689 | ||
| Kinase activity of mutant LRRK2 mediates neuronal toxicity | Q24303603 | ||
| The familial Parkinsonism gene LRRK2 regulates neurite process morphology | Q24317613 | ||
| The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation | Q24318533 | ||
| The protein kinase complement of the human genome | Q24324497 | ||
| Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity | Q24338647 | ||
| Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells | Q24651391 | ||
| Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology | Q28131833 | ||
| LRRK2 in Parkinson's disease: protein domains and functional insights | Q28235024 | ||
| Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease | Q28292932 | ||
| LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity | Q29615144 | ||
| Active and inactive protein kinases: structural basis for regulation | Q29616320 | ||
| Kinase activity is required for the toxic effects of mutant LRRK2/dardarin | Q29620478 | ||
| The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. | Q33292556 | ||
| Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations | Q33942173 | ||
| The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity | Q36154267 | ||
| Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila | Q36891456 | ||
| The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules | Q36982616 | ||
| Mutations in LRRK2 as a cause of Parkinson's disease | Q37039473 | ||
| Expression, purification, and inhibition of human RET tyrosine kinase | Q40440562 | ||
| Autophosphorylation kinetics of protein kinases | Q42161285 | ||
| A study of LRRK2 mutations and Parkinson's disease in Brazil | Q44637069 | ||
| Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction | Q46968375 | ||
| Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation | Q57373779 | ||
| A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease | Q58870346 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 466-478 | |
| P577 | publication date | 2009-01-01 | |
| P1433 | published in | FEBS Journal | Q1388041 |
| P1476 | title | Investigation of leucine-rich repeat kinase 2 : enzymological properties and novel assays. | |
| P478 | volume | 276 |
| Q38832778 | A High-Throughput Screen to Identify LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease Using RapidFire Mass Spectrometry |
| Q54613680 | A new approach to Parkinson's disease: inhibition of leucine-rich repeat kinase-2 |
| Q41279255 | Abberant protein synthesis in G2019S LRRK2 Drosophila Parkinson disease-related phenotypes |
| Q36292502 | Assaying the kinase activity of LRRK2 in vitro. |
| Q35172817 | Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities |
| Q24298093 | Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers |
| Q35780973 | Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. |
| Q43120316 | Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons |
| Q26827527 | Current Understanding Of LRRK2 In Parkinson’s Disease: Biochemical And Structural Features And Inhibitor Design |
| Q37053959 | Decoding Parkinson's Disease Pathogenesis: The Role of Deregulated mRNA Translation |
| Q37479332 | Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization |
| Q33611632 | Development of a mechanism-based high-throughput screen assay for leucine-rich repeat kinase 2--discovery of LRRK2 inhibitors |
| Q37249125 | Development of inducible leucine-rich repeat kinase 2 (LRRK2) cell lines for therapeutics development in Parkinson's disease. |
| Q24305419 | Dominant-negative effects of LRRK2 heterodimers: A possible mechanism of neurodegeneration in Parkinson’s disease caused by LRRK2 I2020T mutation |
| Q50032438 | Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration |
| Q64866880 | Genetic Modifiers of Neurodegeneration in a Drosophila Model of Parkinson's Disease |
| Q22252904 | Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update |
| Q27013695 | Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications |
| Q38044437 | Human leucine-rich repeat kinase 1 and 2: intersecting or unrelated functions? |
| Q38865951 | I2020T mutant LRRK2 iPSC-derived neurons in the Sagamihara family exhibit increased Tau phosphorylation through the AKT/GSK-3β signaling pathway |
| Q28475942 | Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motif |
| Q36780383 | Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization |
| Q34112588 | Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease |
| Q24306788 | Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant |
| Q27026262 | Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease? |
| Q55410950 | LRRK 2 gene mutations in the pathophysiology of the ROCO domain and therapeutic targets for Parkinson's disease: a review. |
| Q38198207 | LRRK2 and neuroinflammation: partners in crime in Parkinson's disease? |
| Q33999270 | LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding |
| Q24338188 | LRRK2 phosphorylates novel tau epitopes and promotes tauopathy |
| Q35288337 | LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice |
| Q38009436 | Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease |
| Q38057769 | Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 – 2011) |
| Q38219430 | Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013). |
| Q37225356 | Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions |
| Q36325784 | Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau. |
| Q24316270 | Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation |
| Q24628425 | Mutant LRRK2 elicits calcium imbalance and depletion of dendritic mitochondria in neurons |
| Q36379938 | Neurite Aggregation and Calcium Dysfunction in iPSC-Derived Sensory Neurons with Parkinson's Disease-Related LRRK2 G2019S Mutation. |
| Q38056875 | Overcoming obstacles in Parkinson's disease |
| Q24314472 | Parkinson-related LRRK2 mutation R1441C/G/H impairs PKA phosphorylation of LRRK2 and disrupts its interaction with 14-3-3 |
| Q38044449 | Pharmacological inhibition of LRRK2 cellular phosphorylation sites provides insight into LRRK2 biology. |
| Q42263195 | Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. |
| Q33595218 | Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis |
| Q38182492 | Prediction of the repeat domain structures and impact of parkinsonism-associated variations on structure and function of all functional domains of leucine-rich repeat kinase 2 (LRRK2). |
| Q36444517 | Premotor biomarkers for Parkinson's disease - a promising direction of research |
| Q24298459 | Rac1 Protein Rescues Neurite Retraction Caused by G2019S Leucine-rich Repeat Kinase 2 (LRRK2) |
| Q34121655 | Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2 |
| Q24294458 | Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease |
| Q27681111 | Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations |
| Q34300430 | Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease |
| Q28482925 | Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation |
| Q36015579 | Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models. |
| Q45143202 | Structural and functional in silico analysis of LRRK2 missense substitutions |
| Q38213378 | Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation |
| Q37139305 | Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease |
| Q48132251 | Synthesis and In Vitro and In Vivo Evaluation of [3H]LRRK2-IN-1 as a Novel Radioligand for LRRK2. |
| Q34236070 | The G2019S pathogenic mutation disrupts sensitivity of leucine-rich repeat kinase 2 to manganese kinase inhibition |
| Q38111307 | The Neurobiology of LRRK2 and its Role in the Pathogenesis of Parkinson’s Disease |
| Q24293505 | The Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an active state conformation leading to increased kinase activity |
| Q33525587 | The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation |
| Q24313336 | The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites |
| Q35235888 | The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity |
| Q37775037 | Understanding the molecular basis of Parkinson's disease, identification of biomarkers and routes to therapy |
| Q92284349 | Vitamin B12 modulates Parkinson's disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection |
Search more.